Search the Newsreel

TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ...

TriSalus Life Sciences Inc (TLSI) announced a new CMS G-code for TriNav reimbursement in office-based labs, significantly expanding market access and supporting full-year 2026 revenue guidance of $54 million to $57 million. While gross margin improved to 86.8%, Q2 revenue growth was modest at …

Harrow Enters Agreement to Acquire Tyrvaya Dry Eye Treatment From Viatris Inc.

Harrow has entered into a definitive agreement to acquire Tyrvaya (varenicline solution), a dry eye nasal spray treatment, from Viatris Inc. This acquisition aims to expand Harrow's dry eye portfolio, complementing its Vevye franchise by offering a differentiated treatment option with a distinct mechanism …

Earnings call transcript: TriSalus tops Q2 revenue forecast, stock slips after hours

TriSalus Life Sciences reported Q2 revenue of $11.4 million, surpassing forecasts, driven by increased adoption of its TriNav system. Despite the revenue beat, the stock slipped after hours due to a wider adjusted EBITDA loss and higher sales and marketing expenses. The company reiterated …

Viatris Inc (VTRS) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance Amid ...

Viatris Inc (VTRS) reported strong Q2 2026 results with $3.8 billion in revenues, a 3.5% operational growth year-over-year, and raised its full-year guidance. Key drivers included robust performance in Greater China and advancements in its R&D pipeline. The company also highlighted challenges such as …

Viatris Inc. Stock 12‑Month Price Target Raised to $18.71, Implies 6% Upside

Viatris Inc. (VTRS) has seen its average 12-month price target raised from $18.14 to $18.71 by 7 analysts, suggesting a 6% potential upside from its August 5th closing price. The consensus analyst rating remains a "Buy," with 5 out of 12 analysts recommending a …

Viatris Inc (VTRS) Shares Fall 7.6% -- GF Value Says Still Overvalued

Viatris Inc (VTRS) shares fell 7.6% to $16.29, which is still 47.7% above its GF Value of $11.03, indicating the stock is significantly overvalued. The company has a GF Score of 58/100, with weak growth potential, and recent insider selling further suggests a cautious …

TriSalus Life Sciences, Inc. 2026: Revenue $11.41M, EPS ($0.16) — 10-Q Summary

TriSalus Life Sciences, Inc. (TLSI) reported its 2026 quarterly results, showing revenue of $11.41M, which was nearly flat year-over-year, and a net loss of ($9.19M), resulting in a diluted loss per share of ($0.16). The company highlighted stable revenue, improved gross margin, continued commercial …

Viatris Inc. stock falls Thursday, underperforms market

Viatris Inc. (VTRS) stock fell 7.71% to $16.29 on Thursday, marking its second consecutive day of losses. This decline occurred during a broader market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing losses.

Viatris Looks to New Launches, Pipeline Progression, and Cost Savings for Long-Term Growth

Viatris, one of the largest generic drug manufacturers globally, aims for long-term growth through new product launches, pipeline progression, and cost savings. While generics face erosion in developed markets, the company plans to focus on complex generics to mitigate pricing and margin pressures. This …

Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook

Viatris has agreed to sell its Tyrvaya nasal spray business to Harrow Inc. for up to $100 million, a move that will allow Viatris to focus on high-potential growth areas like complex generics and transdermal products, and continued investment in the Greater China market. …

Viatris Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VTRS) 2026-08-06

Viatris stock hits 52-week high at 18.27 USD

Viatris Inc. (VTRS) stock reached a 52-week high of $18.07, demonstrating strong investor confidence with a 109.7% return over the past year and a market capitalization of $20.55 billion. InvestingPro analysis suggests the stock is undervalued with a "GOOD" financial health score. Recent positive …

Form 8K Viatris Inc For: 6 August By Investing.com

This article announces that Viatris Inc. has filed a Form 8K on August 6th. The filing is presented without additional details or commentary, focusing solely on the event itself. The article also includes stock performance for VTRS and links to other related market data.

FMR LLC discloses 8.3% Viatris Inc (VTRS) ownership, over 96M shares

FMR LLC has disclosed an 8.3% beneficial ownership in Viatris Inc. (VTRS), amounting to 96,362,102.65 shares. Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over the same shares and stake percentage. This information comes from a SCHEDULE 13G …

Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Viatris (VTRS) reported revenue of $3.76 billion, up 4.9% over the same period last year. EPS came in at $0.69, compared to $0.62 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $3.68 …

Viatris (VTRS) Beats Q2 Earnings and Revenue Estimates

Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Viatris: Bereinigter Gewinn und Umsatz im 2. Quartal steigen; Prognose für 2026 angehoben

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q2 CY2026 Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 4.9% year on year to $3.76 billion. The company expects the full year's revenue to be around $14.75 billion, …

Earnings Flash (VTRS) Viatris Inc. Posts Q2 Adjusted EPS $0.69 per Share, vs. FactSet Est of $0.60

Viatris Inc. (VTRS) reported Q2 adjusted EPS of $0.69 per share, surpassing the FactSet estimate of $0.60. The company also announced Q2 revenue of $3.76 billion, exceeding the FactSet estimate of $3.68 billion.

Viatris Reports Second-Quarter 2026 Financial Results

Viatris Inc. announced strong second-quarter 2026 financial results, with total revenues of $3.8 billion, a 5% reported growth, and Adjusted EBITDA of $1.2 billion, up 8% operationally. The company raised its 2026 financial guidance midpoints, returned approximately $550 million to shareholders, and reduced its …

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow, Inc. NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from …

Inside TriSalus Life Sciences (NASDAQ: TLSI) Q2 2026 performance

Viatris (Nasdaq: VTRS) grows Q2 revenue, raises 2026 outlook

Viatris faces earnings test as pipeline progress meets pricing pressure

Viatris Inc. is preparing to announce its second-quarter earnings, with analysts anticipating $0.61 EPS on $3.67 billion in revenue. Investors are keenly watching whether the company's recent pipeline successes, such as FDA acceptance for fast-acting meloxicam and positive Phase 3 results for VR-205, can …

Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

In its upcoming report, Viatris (VTRS) is predicted by Wall Street analysts to post quarterly earnings of $0.62 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $3.68 billion, representing a year-over-year increase of 2.6%. The …

Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Q2 2026 -- GF Value Sees 20% Upside

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

Viatris (VTRS) is set to announce its second-quarter 2026 earnings on August 6th, with analysts expecting revenues of $3.68 billion and earnings per share of 62 cents. The company's performance will be influenced by factors such as geographical segment sales (Developed Markets, Emerging Markets, …

Is Wall Street Bullish or Bearish on Viatris Stock?

Image by Jakub Zerdzicki via Unsplash With a market cap of $20.5 billion, Viatris Inc. (VTRS) is a global healthcare company committed to empowering people worldwide to live healthier lives at every stage. With a diverse portfolio spanning generics, established brands, and innovative medicines, …

Viatris declares $0.12 quarterly dividend per share By Investing.com

Viatris Inc. announced that its Board of Directors has declared a quarterly dividend of $0.12 per share. This dividend will be paid to shareholders of record as of August 21, 2026, with the payment date set for September 16, 2026. The announcement was made …

Viatris Announces Quarterly Dividend

Viatris Inc. (Nasdaq: VTRS) announced that its Board of Directors declared a quarterly dividend of $0.12 per share. The dividend is payable on September 16, 2026, to shareholders of record as of August 21, 2026. The company also included a section on forward-looking statements …

Sapura Energy : VANTRIS ENERGY SECURES T&I WORK ORDER AND RIG’S NOTICE OF ASSIGNMENT & CONTRACT, REINFORCING FOCUS ON CORE EXECUTION AND ORDER BOOK REPLENISHMENT

Viatris (VTRS) Q2 Earnings Report Preview: What To Look For

Viatris (VTRS) Wins FDA Approval For Gwyn Lo Contraceptive Patch

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Viatris received U.S. FDA approval for its new combined hormonal contraceptive patch, Gwyn Lo. The product is a low dose estrogen contraceptive patch with data …

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

Viatris Inc. (Nasdaq: VTRS) announced it will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m. ET. Investors and the public can listen to the live webcast on the company's investor …

Viatris (VTRS) Stock May Be Cheap Following Its 107% 1 Year Run

PFE5282055 Bond Profile — Key Metrics

This article provides key metrics for the Viatris Inc. (PFE5282055) corporate bond, including its issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. It also offers a brief overview of Viatris Inc.'s business operations and segments. The bond has an issue …